The use of complexed PSA for the early detection of prostate cancer

Anticancer Research

Volumn 25, Issue 3 A, 2005, Pages 1591-1596

  Fischer, Kersten ^a   Loertzer, H ^a   Fornara, P ^a  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

Complexed PSA (c PSA); Free PSA (f PSA); Prostate cancer; PSA

Indexed keywords

COMPLEXED PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; CANCER DIAGNOSIS; COMPLEX FORMATION; CONFERENCE PAPER; CONTROLLED STUDY; EARLY DIAGNOSIS; EVALUATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; ROC CURVE; SERUM; STATISTICAL SIGNIFICANCE;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC DISEASES; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 21244490472     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E and Thun MJ: Cancer statistics - 2003. CA Cancer J Clin 53(1): 5-26, 2003.
2. Andriole GL and Catalona WJ: Using PSA to screen for prostate cancer: The Washington University experience. Urol Clin North Am 20: 647-651, 1993.
3. Coley CM, Barry MJ, Fleming C, Fahs MC and Mulley AG: Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians. Ann Intern Med 126(6): 468-479, 1997.
4. Luboldt HJ, Swoboda A, Borgermann C, Fornara P and Rubben H: Early Detection Project Group of the German Society of Urology: Clinical usefulness of free PSA in early detection of prostate cancer. Onkologie 24(1): 33-37, 2001.
5. Lein M, Stephan C, Jung K, Schnorr D and Loening SA: Molekulare Formen des prostataspezifischen Antigens und des humanen Kallikreins 2 als mögliche Indikatoren in der Prostatakarzinomdiagnostik. Urologe [A] 39: 313-323, 2000.
6. Luboldt HJ and Doehn C: Aufbereitung, Transport und Lagerung der Probe. In: PSA: Der Weg zum Befund. (Fornara P, Semjonow A, eds.) Zuckschwerdt Verlag, pp. 28-32, 2002.
7. Sokoll LJ, Bruzek DJ, Dua R, Dunn W, Mohr P, Wallerson G, Eisenberger M, Partin AW and Chan DW: Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen. Urology 60(4 Suppl 1): 24-30, 2002.
8. Oremek GM, Sapoutzis N, Eden F and Jonas D: Complexed PSA in routine diagnosis. Anticancer Res 23(2A): 975-977, 2003.
9. Jung K, Elgeti U, Lein M, Brux B, Sinha P, Rudolph B, Hauptmann S, Schnorr D and Loening SA: Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? Clin Chem 46(1): 55-62, 2000.
10. Mitchell ID, Croal BL, Dickie A, Cohen NP and Ross I: A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. J Urol 165(5): 1549-1553, 2001.
11. Tello FL, Prats CH and Gonzalez MD: Free and complexed prostate-specific antigen (PSA) in the early detection of prostate cancer. Clin Chem Lab Med 39(2): 116-120, 2001.
12. Okihara K, Fritsche HA, Ayala A, Johnston DA, Allard WJ and Babaian RJ: Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng./ml. J Urol 765(6): 1930-1936, 2001.
13. Tanguay S, Begin LR, Elhilali MM, Behlouli H, Karakiewicz PI and Aprikian AG: Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology 59(2): 261-265, 2002.
14. Djavan B, Remzi M, Zlotta AR, Ravery V, Hammerer P, Reissigl A, Dobronski P, Kaisary A and Marberger M: Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology 60(4 Suppl 1): 4-9, 2002.
15. Okihara K, Cheli CD, Partin AW, Fritche HA, Chan DW, Sokoll LJ, Brawer MK, Schwartz MK, Vessella RL, Loughlin KR, Johnston DA and Babaian RJ: Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol 167(5): 2017-2023; discussion 2023-2024, 2002.
16. Horninger W, Cheli CD, Babaian RJ, Fritsche HA, Lepor H, Taneja SS, Childs S, Stamey TA, Sokoll LJ, Chan DW, Brawer MK, Partin AW and Bartsch G: Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology 60(4 Suppl 1): 31-35, 2002.
17. Lein M, Kwiatkowski M, Semjonow A, Luboldt HJ, Hammerer P, Stephan C, Klevecka V, Taymoorian K, Schnorr D, Recker F, Loening SA and Jung K: A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J Urol 170(4): 1175-1179, 2003.
18. Partin AW, Brawer MK, Bartsch G, Horninger W, Taneja SS, Lepor H, Babaian R, Childs SJ, Stamey T, Fritsche HA, Sokoll L, Chan DW, Thiel RP and Cheli CD: Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 770(5): 1787-1791, 2003.